keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatology;biologics

keyword
https://www.readbyqxmd.com/read/28073800/relationship-between-exposure-to-tumour-necrosis-factor-inhibitor-therapy-and-incidence-and-severity-of-myocardial-infarction-in-patients-with-rheumatoid-arthritis
#1
Audrey S L Low, Deborah P M Symmons, Mark Lunt, Louise K Mercer, Chris P Gale, Kath D Watson, William G Dixon, Kimme L Hyrich
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). METHODS: This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD...
January 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28058538/factors-influencing-the-choice-of-first-and-second-line-biologic-therapy-for-the-treatment-of-rheumatoid-arthritis-real-life-data-from-the-italian-lorhen-registry
#2
Sara Monti, Catherine Klersy, Roberto Gorla, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Raffaele Pellerito, Enrico Fusaro, Giuseppe Paolazzi, Pier Andrea Rocchetta, Ennio Giulio Favalli, Antonio Marchesoni, Roberto Caporali
According to international recommendations, the selection of the biologic disease modifying anti-rheumatic drug (bDMARD) for rheumatoid arthritis (RA) is mainly left to the clinician's preference. We analyzed the real-life factors influencing the first-line choice or the switching strategy, focusing on the prescription of abatacept (ABA) or tocilizumab (TCZ) compared to TNFα inhibitors (TNFi). Patients enrolled in the Lombardy Rheumatology Network (LORHEN) Registry after January 1, 2010, when all considered bDMARD agents were available, were included...
January 5, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28053335/an-fda-perspective-on-the-assessment-of-proposed-biosimilar-therapeutic-proteins-in-rheumatology
#3
REVIEW
Nikolay P Nikolov, Marjorie A Shapiro
Biologic products have revolutionized the management of many rheumatic diseases, but access to these products might be limited by their relatively high costs. The US Biologics Price Competition and Innovation Act of 2009, which is contained within the Patient Protection and Affordable Care Act, established an abbreviated pathway for licensure by the FDA of biologic products that are demonstrated to be biosimilar to or interchangeable with FDA-licensed biologic products, termed reference products. This law allows for the approval of biosimilar biologic products, which are expected to increase access to treatment for patients, and ensuring the implementation of this Act is a high priority for the FDA...
January 5, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28042124/improvement-in-herpes-zoster-vaccination-in-patients-with-rheumatoid-arthritis-a-quality-improvement-project
#4
Heena Sheth, Larry Moreland, Hilary Peterson, Rohit Aggarwal
OBJECTIVE: To improve herpes zoster (HZ) vaccination rates in high-risk patients with rheumatoid arthritis (RA) being treated with immunosuppressive therapy. METHODS: This quality improvement project was based on the pre- and post-intervention design. The project targeted all patients with RA over the age of 60 years while being treated with immunosuppressive therapy (not with biologics) seen in 13 rheumatology outpatient clinics. The study period was from July 2012 to June 2013 for the pre-intervention and February 2014 to January 2015 for the post-intervention phase...
January 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28032846/non-adherence-to-subcutaneous-biological-medication-in-patients-with-rheumatoid-arthritis-a-multicentre-non-interventional-study
#5
Jaime Calvo-Alén, Indalecio Monteagudo, Georgina Salvador, Tomás R Vázquez-Rodríguez, Juan V Tovar-Beltrán, Paloma Vela, Francisco Maceiras, Sagrario Bustabad, José A Román-Ivorra, Consuelo Díaz-Miguel, José Rosas, Enrique Raya, Loreto Carmona, Luis Cea-Calvo, María J Arteaga, Sabela Fernández, Carlos Marras
OBJECTIVES: To evaluate non-adherence to prescribed subcutaneous biologicals in rheumatoid arthritis (RA) patients in Spain. METHODS: ARCO (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs) was a multicentre, non-interventional retrospective study involving 42 rheumatology clinics from representative hospitals throughout Spain. The primary objective was to assess the percentage of patients (aged ≥18 years with an established RA diagnosis) with non-adherence to prescribed subcutaneous biologicals using clinical records and hospital pharmacy dispensing logs as the primary information sources...
December 28, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28003495/efficacy-and-safety-of-anti-tnf-therapies-in-psoriatic-arthritis-an-observational-study-from-the-british-society-for-rheumatology-biologics-register
#6
Amr A Saad, Darren M Ashcroft, Kath D Watson, Deborah P M Symmons, Peter R Noyce, Kimme L Hyrich
No abstract text is available yet for this article.
December 21, 2016: Rheumatology
https://www.readbyqxmd.com/read/28002150/screening-and-treatment-of-latent-tuberculosis-among-patients-receiving-biologic-agents-a-national-and-international-survey-of-rheumatologists
#7
Nhu Quynh Tran, Melinda Garcia-Rosell, Debendra Pattanaik, Syed Hasan Raza, Laura Carbone
OBJECTIVE: We sought to understand the current practice patterns of both US and international members of the American College of Rheumatology (ACR) in this regard. METHODS: A set of questionnaires developed by a focus group of faculties and fellows of the Rheumatology Division of University of Tennessee Health Science Center, Memphis, TN, was sent electronically using an online survey tool to 4433 rheumatologists who are ACR members in the United States and internationally...
January 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/27994990/refractory-case-of-takayasu-arteritis-in-a-young-woman-a-clinical-challenge
#8
Mudassar Ahmed, Salman Mansoor, Salman Assad, Shahar Y Khan, Rizwanullah Khan, Usman Ghani, Taimur Mansoor, Aasim Rehman
Takayasu arteritis (TA) is an idiopathic chronic inflammatory vasculitis of the aorta and its main branches, which if not treated can lead to severe vascular damage and fatal vascular events. Glucocorticoids (GCs) are the mainstay of the therapy of TA but a significant proportion of patients tend to experience flare-ups when their GCs are tapered. We report a case of a 42-year-old female with TA, diagnosed according to the 1990 American College of Rheumatology Criteria for TA. Cardiovascular assessment showed normal carotid upstrokes with bilateral carotid bruits and soft right and left subclavian bruits with weak peripheral pulses...
November 9, 2016: Curēus
https://www.readbyqxmd.com/read/27993144/disease-status-reasons-for-discontinuation-and-adverse-events-in-1038-italian-children-with-juvenile-idiopathic-arthritis-treated-with-etanercept
#9
Sara Verazza, Sergio Davì, Alessandro Consolaro, Francesca Bovis, Antonella Insalaco, Silvia Magni-Manzoni, Rebecca Nicolai, Denise Pires Marafon, Fabrizio De Benedetti, Valeria Gerloni, Irene Pontikaki, Francesca Rovelli, Rolando Cimaz, Achille Marino, Francesco Zulian, Giorgia Martini, Serena Pastore, Chiara Sandrin, Fabrizia Corona, Marta Torcoletti, Giovanni Conti, Claudia Fede, Patrizia Barone, Marco Cattalini, Elisabetta Cortis, Luciana Breda, Alma Nunzia Olivieri, Adele Civino, Rosanna Podda, Donato Rigante, Francesco La Torre, Gianfranco D'Angelo, Mauro Jorini, Romina Gallizzi, Maria Cristina Maggio, Rita Consolini, Alessandro De Fanti, Valentina Muratore, Maria Giannina Alpigiani, Nicolino Ruperto, Alberto Martini, Angelo Ravelli
BACKGROUND: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). METHODS: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000...
December 20, 2016: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/27990762/arthroscopic-guided-synovial-biopsy-in-rheumatology-current-perspectives
#10
REVIEW
Mihir D Wechalekar, Malcolm D Smith
Synovial membrane (SM) pathology has provided valuable insights into our current understanding of immunopathological processes and treatment responses in the inflammatory arthritides. Amongst various methods of synovial biopsy, arthroscopic techniques remain the 'gold standard' owing to better sampling from sites of interest, particularly in patients with partially treated disease and from areas within joints that may be difficult to access using other techniques. Newer sophisticated techniques of SM membrane analyses allow assessment of differentially regulated pathways, the knowledge of which may help elucidate diagnostic and therapeutic targets in an attempt towards developing strategies for personalised medicine in the current era of targeted biologic therapies...
December 19, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/27989589/efficacy-of-triple-association-methotrexate-sulfasalazine-and-hydroxychloroquine-in-early-treatment-of-rheumatoid-arthritis-with-insufficient-response-to-methotrexate-meta-analysis-of-randomized-controlled-trials
#11
Arnaud Mazouyès, Marine Clay, Anne-Catherine Bernard, Philippe Gaudin, Athan Baillet
OBJECTIVES: To evaluate the efficacy of the triple synthetic Disease Modifying Anti-Rheumatic Drugs (sDMARD) combination methotrexate, sulfasalazine and hydroxychloroquine versus a biologic DMARD (bDMARD) in the treatment of early rheumatoid arthritis. METHODS: A systematic literature search was performed using the PubMed and Cochrane databases, and abstracts presented at rheumatology scientific meetings until December 2013. Randomized controlled trials comparing the efficacy and the safety of biologic DMARD with the triple combination were included...
December 15, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/27974925/new-pharmacological-strategies-in-rheumatic-diseases
#12
REVIEW
Schiotis Re, Buzoianu Ad, Mureșanu Df, Suciu S
Targeting the pathogenic pathway of chronic inflammation represents an unmet challenge for controlling disease activity, preventing functional disability, and maintaining an adequate quality of life in patients with rheumatic diseases. Abatacept, a novel molecule that inhibits co-stimulation signal, induces an inhibitory effect on the T-cells. This will further interfere with the activity of several cell lines, leading to the normalization of the immune response. In the latest years, abatacept has been extensively investigated in studies of rheumatoid arthritis for which it was recently approved as a second line biologic treatment in Romania...
July 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27974105/anti-tnf-treatment-response-in-rheumatoid-arthritis-patients-with-moderate-disease-activity-a-prospective-observational-multicentre-study-moderate
#13
Fulvia Ceccarelli, Umberto Massafra, Carlo Perricone, Luca Idolazzi, Roberto Giacomelli, Rosella Tirri, Romualdo Russo, Giovanni Pistone, Piero Ruscitti, Simone Parisi, Pier Paolo Sainaghi, Fabio Cacciapaglia, Alessandro Zullo, Valentina Marino, Alberto Migliore, Guido Valesini
OBJECTIVES: Rheumatoid arthritis (RA) patients with moderate disease activity show progression of joint damage and have impaired quality of life, physical function, work and daily activities. Little is known about management of patients with moderate RA. The aim of the study was to assess the 1-year response to anti-TNF in biologic-naïve RA patients with moderate (3.2 <DAS28 ≤5.1) disease activity despite DMARD treatment, in the Italian clinical practice. METHODS: The MODERATE study is a multicentre prospective, cohort non-interventional study, conducted in 19 Italian rheumatology sites...
December 9, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27974098/use-of-biologic-agents-in-idiopathic-inflammatory-myopathies-in-sweden-a-descriptive-study-of-real-life-treatment
#14
John Svensson, Marie Holmqvist, Anna Tjärnlund, Maryam Dastmalchi, Balsam Hanna, Sara Magnusson Bucher, Ingrid E Lundberg
OBJECTIVES: Biologic treatment has revolutionised treatment in rheumatology in the last decades. Patients with idiopathic inflammatory myopathies (IIM) have so far only been treated with biologics off-label, with little published follow-up on those who are treated and how they are treated. We therefore set out to characterise the Swedish IIM patients who have been treated with biologics. METHODS: By linking Swedish registers we identified 95 patients with IIM who were treated with biologics between 2000 and 2011...
December 9, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27965059/epigenetics-of-psoriatic-disease-a-systematic-review-and-critical-appraisal
#15
Remy A Pollock, Fatima Abji, Dafna D Gladman
Psoriasis is an inflammatory disease of the skin that is sometimes accompanied by an auto-inflammatory arthritis called psoriatic arthritis (PsA). Psoriasis and PsA are multifactorial diseases that result from complex interactions of environmental and genetic risk factors. Epigenetic marks, which are labile chemical marks with diverse functions, form a layer of biological information that sits at the interface of genetics and the environment. Aberrant epigenetic regulation has been previously implicated in other rheumatological disorders...
December 10, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27964757/discordant-inflammation-and-pain-in-early-and-established-rheumatoid-arthritis-latent-class-analysis-of-early-rheumatoid-arthritis-network-and-british-society-for-rheumatology-biologics-register-data
#16
Daniel F McWilliams, Eamonn Ferguson, Adam Young, Patrick D W Kiely, David A Walsh
BACKGROUND: Rheumatoid arthritis (RA) disease activity is often measured using the 28-joint Disease Activity Score (DAS28). We aimed to identify and independently verify subgroups of people with RA that may be discordant with respect to self-reported and objective disease state, with potentially different clinical needs. METHODS: Data were derived from three cohorts: (1) the Early Rheumatoid Arthritis Network (ERAN) and the British Society for Rheumatology Biologics Register (BSRBR), (2) those commencing tumour necrosis factor (TNF)-α inhibitors and (3) those using non-biologic drugs...
December 13, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27957720/-99m-tc-labelled-s-hynic-certolizumab-pegol-in-rheumatoid-arthritis-and-spondyloarthritis-patients-a-biodistribution-and-dosimetry-study
#17
Bieke Lambert, Philippe Carron, Yves D'Asseler, Klaus Bacher, Filip Van den Bosch, Dirk Elewaut, Gust Verbruggen, Rudi Beyaert, Caroline Dumolyn, Filip De Vos
BACKGROUND: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab'-fragment directed against TNF. A biodistribution and dosimetry study was conducted. Tc-S-HYNIC CZP was synthesized. The in vitro TNF neutralizing activity was tested by exposing L929s-cells to various concentrations 99mTc-S-HYNIC CZP and measuring TNF-induced cytotoxicity...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27955647/comparisons-between-comorbid-conditions-and-health-care-consumption-in-rheumatoid-arthritis-patients-with-or-without-biological-disease-modifying-anti-rheumatic-drugs-a-register-based-study
#18
Karin Bengtsson, Lennart T H Jacobsson, Barbro Rydberg, Göran Kvist, Tomas Torstenson, Mats Dehlin, Elisabet Hilme, Anna Lindhé, Susanna Maria Wallerstedt, Helena Forsblad-d'Elia
BACKGROUND: Symptoms and prognosis of patients with rheumatoid arthritis (RA) have improved with more intensive therapy, including the biological disease-modifying anti-rheumatic drugs (bDMARDs). Real life data concerning how comorbidities are distributed among patients treated or not treated with bDMARDs are scarce. Our objective was to investigate differences in comorbidity and health care consumption in RA patients, with and without bDMARDs. METHODS: This cross-sectional study was performed in the Southwestern part of Sweden...
December 12, 2016: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27919202/body-mass-index-is-related-with-the-presence-of-syndesmophyte-in-axial-spondyloarthritis-data-from-the-korean-college-of-rheumatology-biologics-kobio-registry
#19
Seong-Kyu Kim, Jung-Yoon Choe, Shin-Seok Lee, Kichul Shin
OBJECTIVE: We investigated whether body mass index (BMI) is associated with parameters of disease activity and clinical manifestations in axial spondyloarthritis (axSpA). METHODS: Demographic, clinical, and radiological features and disease activity indexes from 789 axSpA patients (619 males and 170 females) were obtained from the Korean College of Rheumatology Biologics (KOBIO) registry. BMI (kg/m(2)) was classified into normal (BMI < 23.0), overweight (23.0 ≤ BMI < 25...
December 6, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27913894/use-and-effectiveness-of-tocilizumab-among-patients-with-rheumatoid-arthritis-an-observational-study-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis
#20
Mari Kihara, Rebecca Davies, Lianne Kearsley-Fleet, Kath D Watson, Mark Lunt, Deborah P M Symmons, Kimme L Hyrich
The aims of the present study are to describe the characteristics of rheumatoid arthritis (RA) patients selected for tocilizumab (TCZ), compare the "real-world" effectiveness of TCZ and tumour necrosis factor inhibitors (TNFi) when used as a first biologic and assess the influence of past biologic exposure/concurrent methotrexate (MTX) therapy on post-TCZ treatment outcomes. The British Society for Rheumatology Biologics Register (BSRBR-RA) is a prospective cohort study following RA patients starting biologics in the UK...
December 2, 2016: Clinical Rheumatology
keyword
keyword
47772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"